2. Search Result
Search Result
Results for "

RET<sup>V804M</sup>

" in MedChemExpress (MCE) Product Catalog:

1402

Inhibitors & Agonists

3

Fluorescent Dye

2

Biochemical Assay Reagents

14

Peptides

1

Inhibitory Antibodies

10

Natural
Products

13

Recombinant Proteins

1230

Isotope-Labeled Compounds

10

Antibodies

6

Click Chemistry

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-136534
    RET V804M-IN-1

    		RET Cancer
    RET V804M-IN-1 (compound 5) is a wt-RET -selective inhibitors of RETV804M kinase, with an IC50 of 20 nM .
    RET V804M-IN-1
  • HY-148742
    RET-IN-21

    		RET Cancer
    RET-IN-21 (compound 5) is a selective RET V804M inhibitor with the IC50 of 0.02 μM. RET-IN-21 does not inhibit the wild type isoforms of RET or KDR. RET-IN-21 has antitumor activity .
    RET-IN-21
  • HY-132193
    RET-IN-4

    		RET Cancer
    RET-IN-4 is a potent, selective and orally active RET inhibitor with IC50s of 1.29 nM, 1.97 nM, and 0.99 nM for RET (WT), RET (V804M), and RET (M918T), respectively. RET-IN-4 exhibits better kinases selectivity against JAK2 (IC50 of 4.4 nM) and FLT3 (IC50 of 30.8 nM). RET-IN-4 has anticancer effects .
    RET-IN-4
  • HY-146710
    RET-IN-16

    		RET Cancer
    RET-IN-16 is a potent and selective RET inhibitor with IC50s of 3.98 nM, 8.42 nM, 15.05 nM, 7.86 nM, 5.43 nM and 8.86 nM for RET(WT), RET(M918T), RET(V804L), RET(V804M), RET-CCDC6 and RET-KIF5B, respectively. RET-IN-16 has anticancer effects .
    RET-IN-16
  • HY-144029
    RET-IN-13

    		RET Cancer
    RET-IN-13 (compound 1), a quinoline compound, is a potent RET inhibitor with IC50s of 0.5 nM, 0.9 nM for RET (WT) and RET (V804M), respectively. RET-IN-13 has the potential for tumors or intestinal diseases related to abnormal activation of RET research .
    RET-IN-13
  • HY-144170
    RET-IN-14

    		RET Btk Cancer
    RET-IN-14 (compound 49) is a potent RET inhibitor with IC50s of <0.51 nM, 9.3 nM, 1.3 nM, 9.2 nM, 15 nM for RET (WT), RET (G810R), RET (V804M), BTK and BTK (C481S), respectively. RET-IN-14 has the potential for tumors research
    RET-IN-14
  • HY-144030
    RET-IN-12

    		RET Others
    RET-IN-12 (compound 2) is a RET inhibitor, with IC50 values of 0.3 nM and 1 nM for RET(WT) and RET(V804M), respectively .
    RET-IN-12
  • HY-170809
    RET-IN-29

    		RET Cancer
    RET-IN-29 (Compound 8W) is a selective RET kinase inhibitor. RET-IN-29 exhibits inhibitory potency against the BaF3 cells harboring CCDC6-RET V804M mutation with an IC50 value of 0.715 μM. RET-IN-29 is promising for research of non-small cell lung cancer (NSCLC) .
    RET-IN-29
  • HY-149099
    RET-IN-22

    		RET Cancer
    RET-IN-22 (compound 17b) is a potent, selective and orally active RET inhibitor with an IC50 of 20.9 nM and 18.3 nM for wild-type RET and RET-V804M, respectively. RET-IN-22 shows highly selective profile to most kinases, especially to EGFR and VEGFR2. RET-IN-22 has anticancer effects .
    RET-IN-22
  • HY-170019
    RET-IN-28

    		RET Cancer
    RET-IN-28 (Compound 16) is a RET (transmembrane receptor tyrosine protein kinase) inhibitor. RET-IN-28 inhibits the activity of the mutant RET enzyme (RET-V804M), and can be applied to cancer research .
    RET-IN-28
  • HY-112950
    RET-IN-1

    		RET Cancer
    RET-IN-1 is a RET kinase inhibitor extracted from patent WO2018071447A1, Compound Example 552, has IC50s of 1 nM, 7 nM, and 101 nM for RET (WT), RET (V804M) , and RET (G810R), respectively .
    RET-IN-1
  • HY-114370
    Selpercatinib
    5+ Cited Publications

    LOXO-292

    		 RET Cancer
    Selpercatinib (LOXO-292) is a potent, selective RET kinase inhibitor with IC50 values of 14.0 nM, 24.1 nM, and 530.7 nM for RET (WT), RET (V804M), and RET (G810R), respectively. Selpercatinib has anticancer activity .
    Selpercatinib
  • HY-151377
    RET-IN-19

    		RET EGFR Aurora Kinase c-Fms MAP4K Cancer
    RET-IN-19 (compound 59) is a potent RET inhibitor, with IC50 values of 6.8 and 13.51 nM against RET-wt and RET V804M, respectively. RET-IN-19 shows anticancer activity. RET-IN-19 can be used for non-small cell lung cancer (NSCLC) research .
    RET-IN-19
  • HY-168105
    RET-IN-27

    		RET Cancer
    RET-IN-27 (compound 20p) is a potent inhibitor of RET, with IC50s of 3.6 nM, 0.1 nM, 2.1 nM, 0.3 nM for RET WT, RET V804L, RET V804M, RET M918T, respectively. RET-IN-27 plays an important role in cancer research .
    RET-IN-27
  • HY-144131
    RET-IN-11

    		Apoptosis RET Cancer
    RET-IN-11 is a potent and selective RET inhibitor with IC50s of 6.20 nM, 18.68 nM for RET and RET V804M, respectively. RET-IN-11 shows anti-proliferation and migration activity in CCDC6-RET-driven LC-2/ad cells. RET-IN-11 induces cell apoptosis .
    RET-IN-11
  • HY-114370R
    Selpercatinib (Standard)

    LOXO-292 (Standard)

    		 Reference Standards RET Cancer
    Selpercatinib (Standard) is the analytical standard of Selpercatinib. This product is intended for research and analytical applications. Selpercatinib (LOXO-292) is a potent, selective RET kinase inhibitor with IC50 values of 14.0 nM, 24.1 nM, and 530.7 nM for RET (WT), RET (V804M), and RET (G810R), respectively. Selpercatinib has anticancer activity .
    Selpercatinib (Standard)
  • HY-153676
    RET-IN-23

    		RET Cancer
    RET-IN-23 (compound 17) is a potent and orally active RET inhibitor with IC50 values of 1.32, 2.50, 6.54, 1.03, 1.47 nM for RET-WT, RET-CCDC6, RET-V804L, RET-V804M, RET-M918T, respectively. RET-IN-23 shows anti-tumor activity .
    RET-IN-23
  • HY-114370S
    Selpercatinib-13C,d3

    LOXO-292-<sup>13sup>C,d3

    		 Isotope-Labeled Compounds Cancer
    Selpercatinib- 13C,d3 (LOXO-292- 13C,d3) is 13C labeled Selpercatinib. Selpercatinib (LOXO-292) is a potent, selective RET kinase inhibitor with IC50 values of 14.0 nM, 24.1 nM, and 530.7 nM for RET (WT), RET (V804M), and RET (G810R), respectively. Selpercatinib has anticancer activity .
    Selpercatinib-13C,d3
  • HY-112301
    Pralsetinib
    10+ Cited Publications

    BLU-667

    		 RET Cancer
    Pralsetinib (BLU-667) is a highly potent, selective RET inhibitor. Pralsetinib (BLU-667) inhibits WT RET, RET mutants V804L, V804M, M918T and CCDC6-RET fusion with IC50s of 0.4, 0.3, 0.4, 0.4, and 0.4 nM, respectively .
    Pralsetinib
  • HY-W759629
    Selpercatinib-d3

    LOXO-292-d3

    		 Isotope-Labeled Compounds RET Cancer
    Selpercatinib-d3 (LOXO-292-d3) is deuterium labeled Selpercatinib. Selpercatinib (LOXO-292) is a potent, selective RET kinase inhibitor with IC50 values of 14.0 nM, 24.1 nM, and 530.7 nM for RET (WT), RET (V804M), and RET (G810R), respectively. Selpercatinib has anticancer activity .
    Selpercatinib-d3
  • HY-139590
    Zeteletinib

    BOS-172738; DS-5010

    		 RET PDGFR Cancer
    Zeteletinib (BOS-172738; DS-5010) is an orally active, selective RET kinase inhibitor with nanomolar potency against RET and >300-fold selectivity against VEGFR2. Zeteletinib shows exquisite potency for the wild type RET, RET V804M/L gatekeeper mutants, and the most common oncogenic RET mutation M918T. Zeteletinib has potent antitumor activity .
    Zeteletinib
  • HY-139590A
    Zeteletinib hemiadipate

    BOS-172738 hemiadipate; DS-5010 hemiadipate

    		 RET PDGFR Cancer
    Zeteletinib (BOS-172738; DS-5010) hemiadipate is an orally active, selective RET kinase inhibitor with nanomolar potency against RET and >300-fold selectivity against VEGFR2. Zeteletinib hemiadipate shows exquisite potency for the wild type RET, RET V804M/L gatekeeper mutants, and the most common oncogenic RET mutation M918T. Zeteletinib hemiadipate has potent antitumor activity .
    Zeteletinib hemiadipate
  • HY-112301R
    Pralsetinib (Standard)

    BLU-667 (Standard)

    		 Reference Standards RET Cancer
    Pralsetinib (Standard) is the analytical standard of Pralsetinib. This product is intended for research and analytical applications. Pralsetinib (BLU-667) is a highly potent, selective RET inhibitor. Pralsetinib (BLU-667) inhibits WT RET, RET mutants V804L, V804M, M918T and CCDC6-RET fusion with IC50s of 0.4, 0.3, 0.4, 0.4, and 0.4 nM, respectively .
    Pralsetinib (Standard)
  • HY-170852
    QZ2135

    		PROTACs RET Cancer
    QZ2135 (compound 20) is a RET-targeted PROTAC degrader with in vivo antitumor properties in a Ba/F3-KIF5B-RET-G810C xenograft mouse model. The degradation activities of QZ2135 targeting KIF5B-RET have DC50 values of 4.7 nM (WT), 17.2 nM (V804M), and 73.8 nM (G810C), respectively. QZ2135 is composed of a target protein ligand (red part) RET ligand-3 (HY-170853), an E3 ligase ligand (blue part) Lenalidomide-F (HY-W039233), and a PROTAC Linker (black part) 7-Iodohept-1-yne (HY-W587352), in which the target protein ligand + linker form a conjugate RET Ligand-Linker Conjugate-1 (HY-170854) .
    QZ2135
  • HY-143615
    RET-IN-10

    		RET Cancer
    RET-IN-10 is a potent inhibitor of RET. RET loss of function mutations leads to Hirschsprung's disease, while its gain of function mutations is associated with a variety of human tumors. RET-IN-10 has the potential for the research of cancer diseases (extracted from patent WO2021135938A1, compound 18) .
    RET-IN-10
  • HY-151987
    RET-IN-20

    		RET Apoptosis Cancer
    RET-IN-20 is a potent RET inhibitor with an IC50 value of 13.7 nM. RET-IN-20 decreases the expression of p-Ret, p-Shc protein. RET-IN-20 induces apoptosis. RET-IN-20 shows antiproliferative and anti-tumor activity .
    RET-IN-20
  • HY-156471
    RET-IN-26

    		RET Cancer
    RET-IN-26 (compound D5) is RET kinase inhibitor, with the IC50 of 0.33 μM .
    RET-IN-26
  • HY-147563
    RET-IN-17

    		RET Cancer
    RET-IN-17 is a potent inhibitor of RET. RET-IN-17 has the potential for the research of pain associated with IBS and other gastrointestinal disorders and for the research of cancers with constitutive RET kinase activity (extracted from patent WO2016038552A1, compound 1) .
    RET-IN-17
  • HY-147564
    RET-IN-18

    		RET Neurological Disease Cancer
    RET-IN-18 is a pyridone compound. is a potent inhibitor of RET. RET-IN-18 is a potent inhibitor of RET. RET-IN-18 has the potential for the research of diseases related to irritable bowel syndrome (IBS) and other gastrointestinal disorders, as well as cancers, and neurodegenerative diseases (extracted from patent WO2022017524A1, compound 1) .
    RET-IN-18
  • HY-N12231
    Carbazomycin B

    		Antibiotic Bacterial Lipoxygenase Infection Cancer
    Carbazomycin B is a bacterial metabolite and can be isolated from Streptomyces. Carbazomycin B is an antifungal and antibacterial agent. Carbazomycin B inhibits 5-lipoxygenase (5-LO) activity in extract from RBL-1 cell with the IC50 Of 1.5 µM [1]sup>[2]sup>[3]sup>[4].
    Carbazomycin B
  • HY-143546
    RET-IN-9

    		RET Cancer
    RET-IN-9 is a potent inhibitor of RET. RET kinase is a single-pass transmembrane receptor tyrosine kinase that plays an important role in the development of the kidney and enteric nervous system, and the maintenance of homeostasis in the nervous, endocrine, hematopoietic, and male reproductive systems. RET-IN-9 has the potential for the research of RET-related disease including non-small cell lung cancer and medullary thyroid cancer (extracted from patent WO2021115457A1, compound 29) .
    RET-IN-9
  • HY-15306S
    Eltrombopag-13C4
    1 Publications Verification

    SB-497115-<sup>13sup>C4

    		 Thrombopoietin Receptor Bacterial Apoptosis Infection Cardiovascular Disease Cancer
    Eltrombopag- 13C4 (SB-497115- 13C4) is 13 sup>C-labeled Z-Eltrombopag. Z-Eltrombopag is an orally active thrombopoietin-receptor non-peptide agonist with platelet-stimulating activity for the study of chronic immune thrombocytopenia. Eltrombopag also has strong inhibitory effects on multidrug-resistant Staphylococcus aureus (Staphylococcus aureus) and can induce apoptosis (apoptosis) in liver cancer cells .
    Eltrombopag-13C4
  • HY-B0141S7
    rel-Estradiol-13C6

    		Isotope-Labeled Compounds Others
    rel-Estradiol- 13C6 is the sup>13C-labeled rel-Estradiol .
    rel-Estradiol-13C6
  • HY-157926
    Nitroso-PSAP

    		Biochemical Assay Reagents Others
    Nitroso-PSAP is a sensitive and specific chromogenic reagent for iron (Fe 2+), which is used for the colorimetric determination of iron in blood after mineralization with periodic acid. TNitroso-PSAP chelates with iron (Fe 2+) to produce a green complex (λmax=756 nm, Epsilon = 4.5 x 10 < sup > 4 < / sup > dm < sup > 3 < / sup > mol < sup > 1 < / sup > cm < sup > 1 < / sup >) .
    Nitroso-PSAP
  • HY-108166
    Hydroxystilbamidine

    		Fluorescent Dye Inflammation/Immunology
    Hydroxystilbamidine, a dye capable of binding to both DNA and RNA, is a powerful inhibitor of cellular ribonucleases. Hydroxystilbamidine is a retrograde fluorescent tracer and a histochemical stain [1]sup .
    Hydroxystilbamidine
  • HY-145128
    GR103545

    		Opioid Receptor Neurological Disease
    GR103545 is a potent and selective agonist of the κ-opioid receptor (κ-OR). 11GR103545 is a radiotracer for imaging κ-OR in vivo [1]sup .
    GR103545
  • HY-126906
    Milbemycin A4

    		Antibiotic P-glycoprotein Cancer
    Milbemycin A4 inhibits P-glycoprotein activity, and reverses multidrug resistance of tumor cells. Milbemycins are a family of macrolide antibiotics with insecticidal and acaricidal activity [1]sup>[2].
    Milbemycin A4
  • HY-W011509
    CyPPA

    		Potassium Channel Neurological Disease
    CyPPA is a positive modulator of hSK3 and hSK2, with EC50 values of 14 μM and 5.6 μM, repectively. CyPPA is inactive on both hSK1 and hIK channels [1]sup .
    CyPPA
  • HY-168868
    RET ligand-2

    		RET Ligands for Target Protein for PROTAC Cancer
    RET ligand-2 is a selective RET inhibitor. RET ligand-2 can serve as a ligand for target protein (Ligands for Target Protein for PROTAC) for the development of PROTAC RET degraders with antitumor activity. RET ligand-2 can be used for the synthesis of RD-23 (HY-168867) .
    RET ligand-2
  • HY-141896
    RET-IN-7

    		RET Cancer
    RET-IN-7 demonstrates potent in vitro RET kinase inhibition and robust in vivo efficacy in RET-driven tumor xenografts upon multiday dosing in mice.
    RET-IN-7
  • HY-174245
    RET-IN-30

    		RET Cancer
    RET-IN-30 (Compound 28) is a RET inhibitor that exhibits inhibitory activity against both wild-type RET and some of its mutants. RET-IN-30 can inhibit the proliferation of A549 cells and has anti-tumor activity .
    RET-IN-30
  • HY-N11122
    7-[α-L-Arabinopyranosyl-(1→6)-β-D-glucopyranosyloxy]cuminol

    		Others Others
    7-[α-L-Arabinopyranosyl-(1→6)-β-D-glucopyranosyloxy]cuminol is a cuminol glycoside. 7-[α-L-Arabinopyranosyl-(1→6)-β-D-glucopyranosyloxy]cuminol can be isolated from Rhodiola rosea sup>[1].
    7-[α-L-Arabinopyranosyl-(1→6)-β-D-glucopyranosyloxy]cuminol
  • HY-144422
    RET-IN-15

    		RET Cancer
    RET-IN-15 is a rearranged during transfection (RET) kinase inhibitor extracted from patent WO2021115457A1 compound 51. RET-IN-15 can be used for the research of cancer .
    RET-IN-15
  • HY-145023
    RET-IN-5

    		RET Cancer
    RET-IN-5 is a potent RET (rearranged during transfection) inhibitor with an IC50s of 0.4 nM and 135.1 nM for RET and VEGFR2, respectively (WO2021213476A1, compound 18) .
    RET-IN-5
  • HY-153941
    RET-IN-24

    		RET Cancer
    RET-IN-24 (Compound 26) is a selective RET tyrosine kinase inhibitor with antitumor activity .
    RET-IN-24
  • HY-143545
    RET-IN-8

    		RET Cancer
    RET-IN-8 is a rearranged during transfection (RET) kinase inhibitor extracted from patent WO2021093720A1 compound I-1. RET-IN-8 can be used for the research of cancer .
    RET-IN-8
  • HY-161119
    Drpitor1a

    		Dynamin Reactive Oxygen Species (ROS) Cardiovascular Disease Cancer
    Drpitor1a is a potent Drp1 inhibitor. Drpitor1a inhibits mitochondrial ROS production, preventes mitochondrial fission, and improves right ventricular diastolic dysfunction during IR (ischemia reperfusion) injury. Drpitor1a has the potential for the research of lung cancer [1]sup .
    Drpitor1a
  • HY-170853
    RET ligand-3

    		PROTACs RET Others
    RET ligand-3 is the ligand for targeting RET PROTAC QZ2135 (HY-170852) .
    RET ligand-3
  • HY-126906R
    Milbemycin A4 (Standard)

    		Reference Standards Antibiotic P-glycoprotein Cancer
    Milbemycin A4 (Standard) is the analytical standard of Milbemycin A4. This product is intended for research and analytical applications. Milbemycin A4 inhibits P-glycoprotein activity, and reverses multidrug resistance of tumor cells. Milbemycins are a family of macrolide antibiotics with insecticidal and acaricidal activity [1]sup> .
    Milbemycin A4 (Standard)
  • HY-145024
    RET-IN-6

    		RET Cancer
    RET-IN-6 is a potent RET (rearranged during transfection) inhibitor with an IC50 of 4.57 nM (CN113461670A, compound 321) .
    RET-IN-6

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: